Drug Trial Radar · NCT02071459
Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA
Last checked: Nov 20, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
107
Actual
Start
Jan 21, 2014
Primary completion
Oct 28, 2019
Study completion Oct 28, 2019
Sponsor
- Lead sponsor
- University Hospital, ToulouseAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 25, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the effects of L-Threo DOPS on orthostatic hypotension symptoms and other non-motor symptoms in patients with Multiple System Atrophy (MSA) after 12 weeks following randomization to continued therapy with droxidopa or placebo.
Conditions
- Multiple System Atrophy
Interventions
L-Threo DOPSDrug
initial dose titration period (4 weeks) followed by 8 weeks at the max tolerated dose
placeboDrug
initial period (4 weeks) followed by 8 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the efficacy of long term efficacy of L-threo DOPSTime frame: 12 weeks
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Centre hospitalier d'Angers
Angers, France
CHU bordeaux
Bordeaux, France
CHU de Clermont-Ferrand
Clermont-Ferrand, France
CHU de Dijon
Dijon, France
CHRU de lille
Lille, France
CHU de limoges
Limoges, France
Hôpital La Timone
Marseille, France
Hôpital G. & R. Laennec
Nantes, France
Hôpital Pitié-Salpétrière
Paris, France
CHU de Poitiers
Poitiers, France
CHU Pontchaillou
Rennes, France
CHU de Rouen
Rouen, France
chu de Strasbourg
Strasbourg, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.